Brief: Kintor Pharma Announces First Patient Dosing In Multi-Regional Global Phase Ii Clinical Trial Of Alk-1 Antibody And Nivolumab Combination Therapy For The Treatment Of Advanced Hepatocellular Carcinoma
04/05/2022 14:58
May 4 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMA ANNOUNCES FIRST PATIENT DOSING IN
MULTI-REGIONAL
GLOBAL PHASE II CLINICAL TRIAL OF ALK-1 ANTIBODY AND NIVOLUMAB
COMBINATION THERAPY FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR
CARCINOMA
Source text for Eikon: ID:nPnbTGZrva
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint